Plain-English translation of NCT05740995 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a combination treatment using anti-PD-1 immunotherapy plus chemotherapy given before surgery for people with locally advanced esophageal squamous cell carcinoma. The medication works by helping your immune system fight cancer cells. Researchers want to understand how well this treatment works and identify biological markers in your blood and tissue that can predict whether you'll respond well to it.
While early studies suggest this medication combined with chemotherapy is safe and feasible, doctors don't yet know how effective it really is at helping patients survive longer or live better. This trial aims to fill that gap and find better ways to predict who will benefit most from this treatment.
You likely qualify if…
You likely don't qualify if…
You would receive the immunotherapy medication combined with chemotherapy before undergoing surgery to remove the cancer. Throughout the trial, you'll have regular clinic visits for treatment, blood tests, and imaging scans to monitor how you're responding. You'll also be asked to donate blood and tissue samples before and after treatment so researchers can study biological markers that predict treatment response. The study involves about 40 patients and is based at a single hospital center.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China